Cheaper drug just as effective protecting heart in duchenne muscular dystrophy

September 24, 2019

COLUMBUS, Ohio - A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in preserving cardiovascular function in boys with Duchenne muscular dystrophy (DMD).

Results of this multi-center trial are in today's Journal of the American Heart Association.

The researchers at The Ohio State University College of Medicine compared spironolactone and eplerenone - two potassium-sparing diuretic medications typically used to treat high blood pressure and help manage heart failure. In their previous work, the team showed that lower dose eplerenone is better than placebo in protecting the heart in boys with DMD.

"Even though it works well, the concern with eplerenone is that it's more costly and less available worldwide," said Dr. Subha Raman, a cardiologist and professor at Ohio State who led the research. "Spironolactone is more commonly available and can cost about 75% less, making it more accessible to everyone who could benefit."

To conduct their trial, researchers enrolled 52 boys with DMD between the ages of 12 and 18 at seven academic medical centers across the country. All of the boys started with preserved cardiac function. After baseline cardiac imaging, participants were randomly assigned to receive 50 mg of eplerenone or spironolactone orally once daily for one year. Neither the patients nor the researchers knew which drug they were assigned.

At the end of 12 months, cardiac function remained stable in both groups, meaning there was no change in the appearance of heart muscle tissue and in pumping capacity. The team reported that stabilization seemed better in this study using a higher dose compared to a prior low-dose study. Importantly, kidney and lung function also remained stable in both groups, and no one experienced serious side effects such as high potassium levels.

"These findings support early therapy as a safe and effective treatment to slow the progression of heart damage in patients at high genetic risk of heart muscle disease, such as those with DMD. The genetic abnormality nearly always advances to heart muscle damage that is a leading cause of death in boys with DMD. Beginning treatment before the first hint of damage, while heart function can be maintained, could have a significant impact on quality and quantity of life," Raman said.

DMD is a genetic disorder in which the body lacks dystrophin, a protein that helps keep muscle cells intact. It causes the skeletal and heart muscles to rapidly degenerate and weaken. DMD predominantly affects males. A majority of patients survive into their 20s or 30s.

"This work will advance how physicians care for young boys with DMD. Rather than simply treating the inevitable damage as it comes, we're now able to significantly delay, and maybe someday prevent, heart failure in DMD," said Dr. K. Craig Kent, dean of the College of Medicine. "Dr. Raman's passion for this work is admirable. Her team's commitment to this research is a great example of Ohio State Wexner Medical Center's mission to improve lives and help people remain productive and healthy at home."

Raman's many years of research was inspired by 32-year-old Ryan Ballou of Pittsburgh, a young man with DMD who, along with his father, started BallouSkies to raise awareness and funding for Raman's research of heart disease in muscular dystrophy patients. BallouSkies, the National Institutes of Health and Parent Project Muscular Dystrophy financially supported this study.
-end-
Disclosure: Raman receives research support through an institutional agreement with Siemens, a manufacturer of MRI equipment used in this study. Siemens had no involvement in this work.

Ohio State University Wexner Medical Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.